Regeneron to Showcase Progress from Innovative Oncology Portfolio in Several Difficult-to-Treat Cancers at ESMO

<p>Event-free survival of investigational use of Libtayo® (cemiplimab) in neoadjuvant cutaneous squamous cell carcinoma (CSCC) from Phase 2 trial to be featured in oral presentation First data for the investigational combination of Libtayo and ubamatamab (MUC16xCD3) in recurrent ovarian cancer also to be presented Additional presentations on outcomes of Libtayo-based therapy in advanced non-small cell [&#8230;]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/regeneron-to-showcase-progress-from-innovative-oncology-portfolio-in-several-difficult-to-treat-cancers-at-esmo/">Regeneron to Showcase Progress from Innovative Oncology Portfolio in Several Difficult-to-Treat Cancers at ESMO</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>